Addressing Health Literacy With a Tailored Survivorship Care Plan
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This clinical trial compares the impact of a tailored survivorship care plan (SCP) to a standard SCP on the understanding of and access to survivorship care in black or African American patients with prostate cancer that has not spread to other parts of the body (localized) or that has spread from where it first started (primary site) to a limited number of places in the body (oligometastatic). SCPs summarize treatment history and recommendations for monitoring and maintaining health, and may also include potential long term effects of treatments received. The intention of a SCP is to help patients participate in their own health care. However, many patients have below basic levels of health literacy, meaning, they have a lower ability to obtain, communicate, process and understand basic health information and services to make health decisions. In fact, poor health literacy has been linked with worse quality of life in prostate cancer survivors. A tailored SCP includes the addition of an educational supplement based on lower reading and writing skills (low literacy) and may address health literacy barriers to understanding of treatment options and side effects. A standard SCP uses a template based on the American Society of Clinical Oncology (ASCO) guidelines for prostate cancer. A tailored SCP with low literacy educational supplements may be more effective compared to a standard SCP in improving understanding and access to survivorship care in black or African American patients with localized or oligometastatic prostate cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyźni czarnoskórzy lub pochodzenia afrykańskiego, którzy przeszli leczenie raka prostaty i obecnie nie mają choroby. Leczenie zakończyli od 1 do 4 lat przed rozpoczęciem badania.
- •Pacjenci, którzy nadal otrzymują leczenie hormonalne po radioterapii w celu kontrolowania raka, a nie w celu łagodzenia objawów.
✗ Disqualifies
- •Osoby z demencją lub zaburzeniami poznawczymi.
- •Osoby, które nie są w stanie świadomie wyrazić zgody na udział w badaniu.
- •Osoby z nawrotem raka prostaty po pierwotnym leczeniu.
- •Osoby poniżej 18 roku życia.
- •Osoby z innym aktywnym nowotworem wymagającym leczenia.
- •Osoby, które nie rozumieją dobrze języka angielskiego, ponieważ materiały badawcze są w tym języku.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 30, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (3)
Grady Memorial Hospital
Atlanta, United States
Emory University Hospital/Winship Cancer Institute
Atlanta, United States
Atlanta VA Medical Center
Atlanta, United States
Trial contact
Kerry L. Kilbridge, MD, MSc
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.